HSIC

Henry Schein (HSIC) receives a #3 (Hold) rating from Zacks with a VGM Score of B. The healthcare solutions company shows solid growth prospects with forecasted year-over-year earnings growth of 7.9% for fiscal 2026. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.36 per share. The company demonstrates a strong average earnings surprise of +6.5%.

In a comparison of two Medical-Dental Supplies stocks, Henry Schein (HSIC) and Merit Medical (MMSI), both holding a Zacks Rank #2 (Buy), HSIC emerges as the superior value opportunity. HSIC has a lower forward P/E ratio of 15.72 compared to MMSI's 20.29, a better PEG ratio of 1.49 versus 1.94, and a lower P/B ratio of 2.46 versus 3.1. HSIC received a Value grade of A while MMSI received a C grade.

Henry Schein (HSIC) is highlighted as a compelling value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an A grade for Value. The stock trades at a P/E ratio of 13.27, significantly below its industry average of 17.20, and demonstrates attractive valuations across multiple metrics including P/B, P/S, and P/CF ratios, suggesting it is currently undervalued in the market.